Compare MTRX & GLSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MTRX | GLSI |
|---|---|---|
| Founded | 1984 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Engineering & Construction | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 311.9M | 372.0M |
| IPO Year | 1995 | 2020 |
| Metric | MTRX | GLSI |
|---|---|---|
| Price | $10.20 | $26.81 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | $17.00 | ★ $50.00 |
| AVG Volume (30 Days) | ★ 204.3K | 145.1K |
| Earning Date | 05-06-2026 | 04-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $769,286,000.00 | N/A |
| Revenue This Year | $18.83 | N/A |
| Revenue Next Year | $9.35 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 5.64 | N/A |
| 52 Week Low | $9.33 | $7.78 |
| 52 Week High | $16.11 | $34.10 |
| Indicator | MTRX | GLSI |
|---|---|---|
| Relative Strength Index (RSI) | 31.72 | 52.06 |
| Support Level | N/A | $21.43 |
| Resistance Level | $12.75 | $29.91 |
| Average True Range (ATR) | 0.43 | 2.26 |
| MACD | -0.02 | 0.21 |
| Stochastic Oscillator | 4.72 | 59.40 |
Matrix Service Co provides engineering, fabrication, construction, maintenance, and repair services prominently to the energy and industrial markets. The company operates through three main segments: Storage and Terminal Solutions, Utility and Power Infrastructure, and Process and Industrial Facilities. These segments cover services like building and maintaining storage tanks and terminals, supporting power delivery and new power generation projects including renewables, as well as plant maintenance and turnarounds for refining and petrochemical industries. Matrix generates revenue by delivering these services to clients in oil, gas, power, and petrochemical sectors across North America and internationally.
Greenwich LifeSciences Inc a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, Flamingo-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences. GP2 is a 9 amino acid transmembrane peptide of the HER2/neu protein, a cell surface receptor protein that is expressed in a variety of common cancers, including expression in 75 percent of breast cancers at low (1+), intermediate (2+), and high (3+ or over-expressor) levels. The combination of GP2 + GM-CSF is called GLSI-100. The company is currently expanding Flamingo-01 into Europe with plans to open up to 150 sites globally.